Impact of Post-diagnosis Weight Change on Survival Outcomes in Black and White Breast Cancer Patients

Lihua Shang  
Harbin Medical University Third Hospital: Tumor Hospital of Harbin Medical University

Masaya Hattori  
Aichi Cancer Center

Gini Fleming  
University of Chicago

Nora Jaskowiak  
University of Chicago

Donald Hedeker  
University of Chicago

Olufunmilayo I Olopade  
University of Chicago

Dezheng Huo (dhuo@uchicago.edu)  
University of Chicago  https://orcid.org/0000-0002-4041-1678

Research article

Keywords: body mass index, weight change, breast cancer, prognosis, racial disparities

DOI: https://doi.org/10.21203/rs.3.rs-67578/v2

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Purpose:** To evaluate weight change patterns over time following the diagnosis of breast cancer, and to examine the association of post-diagnosis weight change and survival outcomes in Black and White patients.

**Methods:** The study included 2,888 women diagnosed with non-metastatic breast cancer in 2000-2017 in Chicago. Longitudinal repeated measures of weight and height were collected, along with a questionnaire survey including questions on body size. Multilevel mixed-effects models were used to examine changes in body mass index (BMI). Delayed entry Cox proportional hazards models were used to investigate the impacts of changing slope of BMI on survival outcomes.

**Results:** At diagnosis, most patients were overweight or obese with a mean BMI of 27.5 kg/m$^2$ and 31.5 kg/m$^2$ for Blacks and Whites, respectively. Notably, about 45% of the patients had cachexia before death and substantial weight loss started about 30 months before death. In multivariable-adjusted analyses, compared to stable weight, BMI loss (>0.5 kg/m$^2$/year) showed greater than 2-fold increased risk in overall survival (hazard ratio [HR]=2.60, 95%CI 1.88-3.59), breast cancer specific survival (HR=3.05, 95%CI 1.91-4.86), and disease-free survival (HR=2.12, 95%CI 1.52-2.96). The associations were not modified by race, age at diagnosis, and pre-diagnostic weight. BMI gain (>0.5 kg/m$^2$/year) was also related to worse survival, but the effect was weak (HR=1.60, 95%CI 1.10-2.33 for overall survival).

**Conclusion:** BMI loss is a strong predictor of worse breast cancer outcomes. Growing prevalence of obesity may hide diagnosis of cancer cachexia, which can occur in a large proportion of breast cancer patients long before death.

Introduction

Obesity is a common health problem in the United States with its prevalence increasing in the past few decades. Obesity is associated with not only an increased risk of many cancers, including postmenopausal breast cancer, but may also impact cancer prognosis and treatment. Body size before or at diagnosis and survival has been studied extensively. A recent meta-analysis reported that for a 5kg/m$^2$ increase in body mass index (BMI) before diagnosis, overall mortality and breast cancer mortality risk increased by 17% and 18%, respectively. However, relatively few studies have investigated the relationship between weight change after diagnosis and survival outcomes in breast cancer patients, with heterogeneous results. Several studies found an association of weight loss with increased risk of mortality. While some studies found an association of weight gain with increased risk of mortality, other studies did not find an association between weight gain and survival.

Most previous studies of weight change only assessed body weight at one time point post-diagnosis, usually within the first two years. Some research relied only on self-reported body weight rather than objectively measured weight. Furthermore, few previous studies of weight change included racial/ethnic minorities in the United States. It is known that obesity prevalence varies across race and ethnicity, and Black women have higher obesity rates compared with other racial/ethnic groups. In the US population, 57% of Black women are obese, while obesity for Hispanic women is 47%, 39% for White women and 12% for Asian American
women. Due to heterogeneity of disease phenotypes and treatments, several questions remain about weight change and survival for Black women in the US with breast cancer. While it is well documented that Black women with breast cancer have higher mortality rates compared with other racial/ethnic groups in the US, it remains unclear whether higher prevalence of obesity in Black women contributes to the racial disparity in breast cancer mortality. It is also unclear whether there are racial differences in patterns of weight change after breast cancer diagnosis and if so, how these different patterns of weight change effect breast cancer survival.

To address these knowledge gaps, we used electronic health records and survey data from a large, multi-ethnic cohort of women diagnosed with breast cancer between 2000-2017 and treated at the University of Chicago Medicine to evaluate weight change patterns over time by race and ethnicity, and to examine the effect of post-diagnosis weight change on survival outcomes. To the best of our knowledge, this is a large single institution study to examine serial weight changes using multiple measurements from electronic health records and identifies significant real world evidence for the effect of weight change on cancer mortality in Black women in the US.

**Patients And Methods**

**Study population**

The Chicago Multiethnic Epidemiologic Breast Cancer Cohort (ChiMEC) was initiated as a hospital-based case-control study to facilitate research on the effects of high-penetrance susceptibility genes, common genetic variants, and environmental risk factors for breast cancer. Breast cancer cases were followed for survival, disease recurrence, and other outcomes to form the ChiMEC cohort. Patients diagnosed or treated at the University of Chicago Hospitals were ascertained through the cancer risk clinic established in 1992. In 2008, the study was expanded to recruit all breast cancer patients evaluated in the institution. Clinical, pathological, and treatment data were collected via electronic medical records. Epidemiological risk factor data were collected via a structured questionnaire. A biobank was established, collecting blood and tumor samples, including both fresh frozen and formalin-fixed, paraffin-embedded tumor blocks. Enrollment and follow-up of the patients is on-going. This analysis includes female patients who were ≥ 18 years of age at diagnosis, enrolled in the ChiMEC study between 2000 and 2017, had histologically diagnosed non-metastatic breast cancer, and available body weight and height data. The study protocol was approved by the institutional review board of the University of Chicago.

**Measurement of body weight and height**

Body weight was measured repeatedly and recorded in electronic health records in the hospitals. We also conducted phone or online interview survey and asked patient's body weight and height in 19 months after diagnosis on average. In a subset of 1,524 patients, both measured and self-reported weights were available on similar dates (difference between dates of measurement and interview <6 months, median 34 days separation). Self-reported and measured weights of these patients were highly correlated, with a Lin's concordance correlation coefficient of 0.968 (Figure 1). On average, measured weight was 1.5 kg higher than self-reported weight. Because of this high correlation, we utilized calibrated weights at date points without measured weights but with self-reported weights; the calibrated weights were calculated from reduced major axis (RMA)
regression. At date points with measured weights, we took the values directly. The self-reported and measured heights were also highly correlated with a concordance correlation coefficient of 0.960 and an average difference of 0.2 cm.

BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m\(^2\)) and categorized according to the World Health Organization definition: underweight (<18.5 kg/m\(^2\)), normal weight (18.5-24.9 kg/m\(^2\)), overweight (25.0-29.9 kg/m\(^2\)), or obese (≥ 30 kg/m\(^2\)).

**Covariates**

Demographic and lifestyle data were collected at baseline, and included race, ethnicity, gender, age at diagnosis, smoking history, and insurance status. Clinical data included date of diagnosis, tumor stage, tumor size, number of lymph nodes involved, histological type, histological grade, estrogen receptor status, progesterone receptor status, HER2 status, surgery, chemotherapy, radiotherapy, and hormonal therapy. Comorbidity status was represented as Deyo/Charlson comorbidity index,\(^{21}\) which was a cumulative score of 15 health conditions at date of breast cancer diagnosis.

**Survival outcomes**

Patient outcomes were collected from the University of Chicago Cancer Registry and records of clinical visits, and through periodic searches of the National Death Index. Outcomes were death due to all-cause mortality, death due to breast cancer, loco-regional and distant recurrence, and second primary breast cancer. We examined three survival endpoints using delayed entry Cox proportional hazards models.\(^{10}\) Time since diagnosis was used as the time scale. The entry date in the Cox model was the date of last post-diagnosis weight measurement, rather than date of diagnosis to avoid survivors’ bias. The exit dates for the three survival outcomes were specified differently. In the overall survival analysis, it was the date of death from any cause or last date of follow-up. The exit date of breast cancer-specific mortality analysis was the date of death due to breast cancer or last date of follow-up. The exit date of disease-free survival was the date of recurrence, second primary breast cancer, death or last date of follow-up, whichever came first.

**Statistical analyses**

Baseline demographic and clinical factors were compared between racial/ethnic groups using chi-square tests for categorical variables and linear regression models for continuous variables. To examine factors related to post-diagnostic weight change, we fit three-level mixed-effects regression models for BMI.\(^{22}\) The first-level consisted of the BMI values at each time point, which were nested within second-level time periods, and then within third-level individual patients. We specified 5 time periods: time at diagnosis, then at <12 months, 12-24 months, 24-36 months, and 36-60 months post diagnosis. BMI at diagnosis refers to any weights measured between <1 year before diagnosis and before any cancer therapy. We included second and third-level random intercepts, and third-level random slopes in the models to account for correlation among BMIs within time periods and individuals. On average, there were 31 BMI measures per patient, but because the number of observations per patient varied largely across patients, we utilized three-level rather than two-level models to avoid undue influence from patients having many recorded observations. In addition, we modeled the shape of
BMI changes according to months before death or censoring using restricted cubic spline functions in the mixed-effects model, after stratification by vital status in both White and Black women.

We used a two-step approach to examine the impact of weight change on survival outcomes. In the first step, for each subject, we fit fixed-effect linear regression models of BMI measured at least one year before the last follow-up or death (to reduce the influence of drastic weight before death). In the second step, the slopes from the linear models (BMI changes per year) were included as an independent variable in delayed entry Cox proportional hazards models. In multivariable models, we adjusted for age, race, Carlson comorbidity index, tumor stage, histologic grade, molecular subtypes, radiotherapy, hormonal therapy, and chemotherapy. To explore whether recurrence influence the association between weight change and overall survival, we modeled recurrences as a time-varying covariate in Cox model. We also conducted stratified analysis according to race, baseline BMI, and age at diagnosis. For sensitivity analyses, we estimated slopes of BMI changes using only BMI data within the first two years after diagnosis, and calculated BMI changes between baseline and 18 months post-diagnosis. In addition to the two-step approach, we jointly modeled longitudinal and survival data using a mixed-effects model and Weibull survival model, and found the results are similar. As two-step approach is faster and more flexible (allowing Cox model), we did not present the Weibull model results. Statistical analyses were conducted using the STATA 15 software package (StataCorp, College Station, TX).

Results

Of the 2,888 breast cancer patients in the study cohort, 1,575 (54%) were non-Hispanic White, 1,106 (39%) Black, 126 (4%) Asian, and 81 (3%) Hispanic. Baseline demographic and clinical characteristics by racial/ethnic groups are summarized in Table 1. Compared to non-Hispanic White, Black women were older, more likely to smoke currently, receive Medicare or Medicaid benefits, and have comorbidities. As expected, Black women were more likely to have triple-negative breast cancer. The distribution of tumor stage was similar among the groups. Black women had the highest BMI at diagnosis (mean 31.5 kg/m\(^2\)) with 30.9% being overweight and 51.8% obese, followed by Hispanic, and non-Hispanic Whites, while Asian Americans had the lowest BMI (Figure 2A).

As shown in Figure 2B-E, Black patients had significant weight loss after 6 months, 18 months, 30 months, and 48 months from diagnosis (0.84 kg/m\(^2\) reduction), while body weight did not change substantively in other racial/ethnic groups. Patients younger than 50 gained weight after diagnosis, while older patients lost weight. Patients with at least one comorbidity lost substantial weight after diagnosis. In the multivariable analysis using a mixed-effects linear model, we found that Black patients had higher BMI at diagnosis but had significant weight loss after cancer diagnosis (0.47 kg/m\(^2\)/year reduction) compared with Whites (Table 2). Older patients or patients with comorbidities had higher BMI at diagnosis but had significantly more weight loss after diagnosis, compared with younger patients or those without comorbidities, respectively. Patients diagnosed with different tumor stages had similar baseline weight but those with advanced stage had larger weight loss in a long run. At baseline, patients with or without chemotherapy had similar body weight; at months 6 and 18, patients receiving chemotherapy had more weight loss than patients without chemotherapy, but at month 48 after diagnosis, patients receiving chemotherapy had slightly less weight loss. We also found ex-smokers at diagnosis had higher baseline BMI and lost more weight during follow-up.
After a median follow-up time of 6.4 years, 387 patients died (190 deaths due to breast cancer) and 265 patients had a breast cancer recurrence. We modeled the shape of BMI changes according to months before death or censoring stratified by vital status in both White and Black women (Figure 3). Among breast cancer survivors, BMI was almost constant during the follow-up years in both White and Black women. In contrast, for patients who died, there were large BMI losses starting about 30 months before death with the rapid BMI reduction observed in both Whites and Blacks (3.2 and 3.8 kg/m\(^2\) reduction, respectively). These BMI reductions were equivalent to 8.8 and 10.3 kg absolute weight loss for an average person in our cohort. Using a consensus definition of cancer cachexia,\(^{24}\) about 45% of the patients who were deceased had cachexia (40% in Whites and 48% in Blacks). The median time from recurrence to death was 24 months and 13 months for Whites and Blacks who were deceased, respectively. For patients who had distant metastasis and died later, 19% had cachexia before the recurrence.

Being obese or overweight at diagnosis was significantly associated with higher risk of all-cause mortality, breast cancer specific mortality, and disease recurrence in the univariate analysis. However, after adjusting for age, race, Carlson comorbidity index, tumor stage, histologic grade, estrogen receptor, progesterone receptor, Her2, radiotherapy, hormonal therapy, and chemotherapy, BMI at baseline was no longer statistically associated with survival outcomes (Table 3).

Table 4 shows that after adjustment for multiple clinical and pathological factors, compared to stable weight, BMI loss (>0.5 kg/m\(^2\)/year) was associated with a higher risk of all-cause mortality (hazard ratio [HR]=2.60, 95% CI 1.88-3.59), breast cancer specific mortality (HR=3.05, 95% CI 1.91-4.86), and disease-free survival (HR=2.12, 95% CI 1.52-2.96). BMI gain (>0.5 kg/m\(^2\)/year) was also associated with worse survival outcomes compared with stable weight (HR=1.60, 95% CI 1.10-2.33 for overall survival; HR=1.73, 95% CI 1.04-2.87 for breast cancer-specific survival, and HR=1.54, 95% CI 1.06-2.24 for disease-free survival). A slope of 0.5 kg/m\(^2\)/year is equivalent to 3% weight change over 18 months for women with BMI of 25 kg/m\(^2\) (i.e. 5’5 height and 150 pounds weight). There was a U-shaped relationship between change in BMI and overall survival (Figure 4, p-for-nonlinearity <0.001). The larger the weight loss, the higher the risk of all-cause mortality, and BMI gain was also associated with gradual increased risk of death. Similar U-shaped relationships were also observed for breast cancer-specific survival and disease-free survival.

In addition, we found that age was strongly associated with overall survival and disease-free survival, and moderately associated with breast cancer-specific survival (Table 4). There was a monotonic strong association between higher comorbidity index with worse outcomes in overall survival and disease-free survival, but no association between comorbidity and breast cancer-specific survival. Tumor stage was strongly associated with all three survival outcomes, in particular with breast cancer-specific survival (HR=5.92, 95% CI 3.35-10.48, comparing stage 3 vs. stage 1). Black women had about a 2-fold increased risk of the three survival outcomes compared with White women (Table 4). Consistent with a previous clinical trial-based study,\(^{25}\) we also found that the racial difference in overall survival was stronger among non-obese patients (HR=2.22, 95% CI 1.48-3.33) than among obese patients (HR=1.28, 95% CI 0.82-1.98).

We also included recurrence status as a time-varying covariate in the Cox model of overall survival, and found that relationship between weight change and overall survival remained: compared to stable weight, BMI loss (>0.5 kg/m\(^2\)/year) was associated with a higher risk of all-cause mortality (HR=2.55, 95% CI 1.84-3.53); BMI
gain (>0.5 kg/m$^2$/year) was also associated with worse survival compared with stable weight (HR=1.62, 95% CI 1.10-2.39). As expected, recurrence status strongly predicted overall survival (HR=13.09, 95% CI 9.76-17.56).

In the stratified analysis of changing slope of BMI and survival outcomes, we found the U-shaped relationships were generally preserved for White and Black patients (**Table 5**): both weight gain and loss after diagnosis were associated with increased risk of the three outcomes. Although the effects were seemingly stronger in Blacks than in Whites, the tests for interaction were not statistically significant. The effects of BMI change on survival outcomes seemed to be limited to those women who were overweight/obese at diagnosis, but the test for interaction were not significant. BMI loss was consistently associated with worse survival outcomes regardless of the age at diagnosis.

We further examined whether the slope of BMI change within the first two years after diagnosis and BMI change from diagnosis to 18 months can predict survival outcomes (**Table 6**). We found that weight loss within the first 2 years of diagnosis can predict increased risk of the three survival outcomes after adjustment for other prognostic factors. Using changing slope as a measure of weight loss was more powerful in risk prediction than change between two time points, reflecting more data being efficiently utilized.

**Discussion**

In this multiethnic cohort of breast cancer patients, we demonstrated a U-shaped relationship of weight change after diagnosis with all-cause mortality, breast cancer-specific mortality, and disease-free survival. We did not find this relationship significantly different across race, age at diagnosis and pre-diagnostic weight subgroups. The associations between weight loss and survival outcomes were strong, while the associations between weight gain and survival outcomes were weak. We also identified several factors related to weight change after breast cancer diagnosis.

We found that the patterns of post-diagnosis weight change varied by race, age, comorbidity, and tumor stage. Of interest, Black women who had the highest BMI at diagnosis (>80% obese/overweight) also had the most post-diagnosis weight loss. Patients with any comorbidities had quite large weight loss (0.5 kg/m$^2$/per year) and having comorbidities can strongly predict worse overall survival but not breast cancer-specific survival. It is possible that weight loss is an indicator of unstable comorbidity conditions. Advanced stage patients actually lost more weight, which may reflect that advanced stages predict worse survival and weight loss is a forerunner of death as shown in this and previous studies.$^6$-$^1^1$ We found patients undergoing chemotherapy lost more weight than those without chemotherapy around the time of chemotherapy administration (within 18 months), possibly due to toxicities of chemotherapy (nausea, vomiting, and diarrhea), but in long-run, they lose less weight than patients without chemotherapy. This is consistent with a meta-analysis, which documented weight gain during chemotherapy,$^2^6$ although most studies in the meta-analysis examined short-term weight change while we examined long-term weight change.

By using BMI changing slope (rate of weight loss over time), we showed strong associations between weight loss and all three survival outcomes. Although different definitions of weight loss have been used across studies, our study findings are consistent with previous studies,$^6$-$^1^1$,$^2^7$ which were mostly conducted in White patients. Interestingly, one study found a stronger association between weight loss and overall mortality and
breast cancer-specific mortality in Chinese compared to White patients.\textsuperscript{10} We found somewhat stronger effects, but not statistically significantly, in Black women than in White women. Taken together, it is reasonable to conclude that post-diagnosis weight loss is associated with worse survival in breast cancer patients, though the effect size might be different across populations. We also showed that even among women who were overweight/obese at diagnosis, weight loss did not confer a survival advantage, which is consistent with previous studies.\textsuperscript{6,9,10} To mimic previous studies, we also restricted the analysis to weight change within the first two years after diagnosis, and still found that weight loss in the first two years was a predictor for worse survival but the effect was attenuated compared with using all available data.

The underlying reasons for the consistent, strong association between weight loss and elevated mortality are not very clear. It is possible that patients have pre-cachexia or cachexia because of cancer treatment, tumor progression (tumor-induced inflammation), or deterioration of comorbidities. Cachexia was defined as weight loss $\geq 5\%$ over past six months, and traditionally it is viewed as an end-of-life condition in patients with advanced malignancies.\textsuperscript{24} However, we found that rapid weight loss started about 30 months before death in both White and Black patients. As a benchmark, the median time from recurrence to death in those who died was 24 months for White and 13 months for Black patients, so some deceased patients (19\%) had already had cachexia before distant recurrences. This alarming observation suggests that cancer cachexia can be present early during cancer progression, which warrants further investigation and attention from clinicians. Earlier diagnosis of cancer cachexia may be important to initiate multimodal management plans including nutritional support, exercise, active anticancer therapy, and even palliative care for some patients. Cachexia is a complex metabolic condition and often involves severe depletion of skeletal muscle or sarcopenia.\textsuperscript{24,28,29} Sarcopenia was found to be an independent predictor of cancer outcomes.\textsuperscript{30-32} Similar to most large observational studies, we did not collect information on intentionality of weight loss. We postulate that most weight loss is non-intentional in our study. Although intentional weight loss has been demonstrated to be feasible and safe in the short-term among breast cancer patients,\textsuperscript{33-35} we are still waiting for results from two ongoing randomized clinical trials on the effects of intentional weight loss on cancer recurrence and survival.\textsuperscript{36,37}

With regard to post-diagnosis weight gain and survival, previous studies gave inconsistent results. Some studies found positive association between weight gain and increased risk of all-cause mortality,\textsuperscript{6,8,9,12} while others did not.\textsuperscript{10,11} A meta-analysis reported large weight gain ($\geq 10.0\%$) was associated with all-cause mortality (HR=1.23), but not for moderate weight gain (5-10\%: HR=0.97).\textsuperscript{38} A study published after the meta-analysis failed to show the association between large weight gain and overall survival.\textsuperscript{11} There were also inconsistencies in terms of breast cancer-specific survival and/or breast cancer recurrence; some studies found association between weight gain with increased risk of breast cancer mortality,\textsuperscript{6,8,12} but others did not.\textsuperscript{10,11} Our primary analysis in the ChiMEC cohort used the rate of weight change over time (i.e. slope) rather than change between two selected time points. We found that hazard ratios for the three survival outcomes were more than 1.5 when comparing women with weight gain slope $>0.5$ kg/m$^2$/year to women with stable weight (weight change $\leq 0.5$ kg/m$^2$/year), and the strength of association was stronger in Black women than in White women, though the tests for interaction were not significant. When we restricted the analysis to weight change in the first two years post-diagnosis, no statistically significant associations were found between weight gain and mortality. Taken together, the association between post-diagnosis weight-gain and survival outcomes are quite
weak, so it is statistically significant only for large weight gain or using a more sensitive analytical approach. It is interesting to further investigate whether weight gain after diagnosis has different impact on survival across racial/ethnic populations. There are several possible mechanisms for the association between weight gain and elevated mortality. Weight gain, most likely gain of fatness, could increase circulating estrogens, while estrogens promote the growth of estrogen-dependent breast tumors. Several clinical trials demonstrated that aromatase inhibitors were not fully effective for hormone receptor–positive breast cancer patients who were obese. Weight gain, particularly in overweight and obese patients, could alter levels of leptin and adiponectin, and induce abnormal glucose metabolism. Several studies showed that diabetes and biomarkers of glucose metabolism were associated with breast cancer death.

The study has several strengths. It is based on a relatively large, racially diverse sample, enhancing the generalizability of the study findings. Another strength is that the study collected longitudinal repeated measures of body size after diagnosis, and analyzed the data sufficiently using state-of-the-art methods. We calculated changing rate (slope) of BMI using fixed effect linear models, as opposed to previous studies that measured weight change at a single time point after diagnosis. Our method is more accurate and reliable because it utilized all available data points and accounted for timing of measurement. As shown in Table 6, BMI changing slope gave more reliable and clear-cut interpretable results.

Several limitations need to be considered. First, some weight data were self-reported. Fortunately, at time points when we have both self-reported and measured weights, we found excellent agreement, suggesting that the self-reported weights were reliable in our cohort. There was a systematic under-reporting of weight (1.5 kg on average), which may reflect a social desire of lower weight or wearing less clothes when measuring weight at home than at hospital. We did a calibration to self-reported weights so the data should be reliable. Second, we do not know if the weight loss is intentional or not, so one should be cautious when interpreting the finding on weight loss's effects. The large weight loss before death is most likely unintentional. Intentional weight loss, especially weight loss due to exercise, could be beneficial for breast cancer survivors. Results from several ongoing trials should shed light on this question.

**Conclusions**

In summary, this study of breast cancer patients demonstrates that both weight gain and loss are associated with an adverse breast cancer prognosis, and maintaining stable weight is associated with better survival outcomes. In addition, the study suggests that cancer cachexia could start as early as 30 months before death. These findings have important implications for clinical practice. Clinicians should be aware that sudden unknown weight loss, regardless of a patient's race, initial body weight, and age, may be a sign of poor prognosis, and require a more personalized approach to disease management ranging from nutritional support to active cancer therapy.

**Declarations**

**Ethical Approval and Consent to Participate**

The study has been approved by the institutional review board of the University of Chicago (protocol number 16352A). All participants gave their written informed consent to participate with the possibility to withdraw from
the study at any time.

**Consent for publication**

Not applicable

**Availability of supporting data**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

O.I. Olopade is an equity stock holder of CancerIQ and Tempus. Other authors declare no conflicts of interest.

**Funding**

This project was supported by National Cancer Institute (P20 CA233307 to O.I. Olopade and D. Huo) and the Breast Cancer Research Foundation (to O.I. Olopade and D. Huo).

**Authors’ contributions**

D. Huo and O.I. Olopade designed the study. D. Huo, O.I. Olopade, and N. Jaskowiak collected the data. D. Huo, L. Shang, M. Hattori, and D. Hedeker analyzed the data. L. Shang wrote the initial manuscript draft. All authors helped with the interpretation of the data. All authors read, edited, and approved the final manuscript.

**Acknowledgements**

The authors are grateful to the participants and staff of the ChiMEC study.

**References**

1. Fryar CD, Kruszon-Moran D, Gu Q, Ogden CL. Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016. Natl Health Stat Report. 2018: 1-16.

2. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384: 755-765.

3. World Cancer Research Fund/American Institute for Cancer Research. Continous Update Project Expert Report 2018. Diet, Nutrition, Physical Activity and Breast Cancer, 2018.

4. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013;105: 1344-1354.

5. Chan DS, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25: 1901-1914.

6. Bradshaw PT, Ibrahim JG, Stevens J, et al. Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology. 2012;23: 320-327.
7. Caan BJ, Kwan ML, Hartzell G, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes & Control. 2008;19: 1319-1328.
8. Nichols HB, Trentham-Dietz A, Egan KM, et al. Body Mass Index Before and After Breast Cancer Diagnosis: Associations with All-Cause, Breast Cancer, and Cardiovascular Disease Mortality. Cancer Epidemiology Biomarkers & Prevention. 2009;18: 1403-1409.
9. Chen X, Lu W, Zheng W, et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 2010;122: 823-833.
10. Caan BJ, Kwan ML, Shu XO, et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev. 2012;21: 1260-1271.
11. Cespedes Feliciano EM, Kroenke CH, Bradshaw PT, et al. Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2017;26: 44-50.
12. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23: 1370-1378.
13. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. Jama. 2016;315: 2284-2291.
14. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67: 439-448.
15. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat. 2011;129: 565-574.
16. Lu Y, Ma H, Malone KE, et al. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol. 2011;29: 3358-3365.
17. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama. 2005;294: 1925-1933.
18. Huo D, Senie RT, Daly M, et al. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009;27: 1184-1190.
19. Huo D, Feng Y, Haddad S, et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human molecular genetics. 2016;25: 4835-4846.
20. Huo D, Zheng Y, Ogundiran TO, et al. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012;33: 835-840.
21. Deyo R. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology. 1992;45: 613-619.
22. Hedeker D, Gibbons RD. Longitudinal Data Analysis. New York: John Wiley & Sons, 2006.
23. Crowther MJ, Abrams KR, Lambert PC. Joint modeling of longitudinal and survival data. The Stata Journal. 2013;12: 165-184.
24. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12: 489-495.

25. Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015;33: 2353-2360.

26. van den Berg MM, Winkels RM, de Kruif JT, et al. Weight change during chemotherapy in breast cancer patients: a meta-analysis. BMC Cancer. 2017;17: 259.

27. Marinho LA, Rettori O, Vieira-Matos AN. Body weight loss as an indicator of breast cancer recurrence. Acta Oncol. 2001;40: 832-837.

28. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16: 153-166.

29. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62: 265-279.

30. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018;4: 798-804.

31. Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31: 1539-1547.

32. Villasenor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012;6: 398-406.

33. Goodwin PJ, Segal RJ, Vallis M, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 2014;32: 2231-2239.

34. Stolley M, Sheean P, Gerber B, et al. Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors. J Clin Oncol. 2017;35: 2820-2828.

35. Reeves MM, Terranova CO, Eakin EG, Demark-Wahnefried W. Weight loss intervention trials in women with breast cancer: a systematic review. Obes Rev. 2014;15: 749-768.

36. Ligibel JA, Barry WT, Alfano C, et al. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017;3: 37.

37. Rack B, Andergassen U, Neugebauer J, et al. The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel). 2010;5: 395-400.

38. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2015;107: djv275.

39. Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev. 2011;12: 282-294.

40. Azrad M, Demark-Wahnefried W. The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep. 2014;3: 9-15.

Tables
Table 1. Characteristics of 2888 patients in the Chicago multiethnic epidemiologic cohort of breast cancer study*
| Characteristic                        | White | Black | Asian | Hispanic | P      |
|--------------------------------------|-------|-------|-------|----------|--------|
| **N**                                | 1575  | 1106  | 126   | 81       |        |
| **Age at diagnosis, n (%)**          |       |       |       |          |        |
| <40                                  | 147 (9.3) | 86 (7.8) | 17 (13.5) | 15 (18.5) | <0.001 |
| 40-49                                | 432 (27.4) | 191 (17.3) | 48 (38.1) | 23 (28.4) |        |
| 50-59                                | 463 (29.4) | 262 (23.7) | 25 (19.8) | 14 (17.3) |        |
| 60-69                                | 334 (21.2) | 262 (23.7) | 25 (19.8) | 15 (18.5) |        |
| 70+                                  | 199 (12.6) | 305 (27.6) | 11 (8.7)  | 14 (17.3) |        |
| **mean (SD)**                        | 54.7 (12.3) | 59.6 (13.9) | 51.1 (12.5) | 53.8 (14.5) | <0.001 |
| **Smoking status, n (%)**            |       |       |       |          |        |
| Never smoker                         | 968 (63.5) | 597 (55.2) | 105 (90.5) | 48 (62.3) | <0.001 |
| Previous smoker                      | 416 (27.3) | 313 (29.0) | 9 (7.8)   | 23 (29.9) |        |
| Current smoker                       | 140 (9.2)  | 171 (15.8) | 2 (1.7)   | 6 (7.8)   |        |
| **Insurance status, n (%)**          |       |       |       |          |        |
| No                                   | 7 (0.4)   | 2 (0.2)   | 0 (0.0)   | 1 (1.2)   | <0.001 |
| Private                              | 1149 (73.0) | 433 (39.2) | 95 (75.4) | 52 (64.2) |        |
| Medicaid                             | 37 (2.3)   | 166 (15.0) | 4 (3.2)   | 5 (6.2)   |        |
| Medicare                             | 346 (22.0) | 476 (43.0) | 25 (19.8) | 22 (27.2) |        |
| Other/unknown                        | 36 (2.3)   | 29 (2.6)   | 2 (1.6)   | 1 (1.2)   |        |
| **Carlson comorbidity index, n (%)** |       |       |       |          |        |
| 0                                    | 1318 (83.7) | 762 (68.9) | 108 (85.7) | 63 (77.8) | <0.001 |
| 1                                    | 114 (7.2)   | 134 (12.1) | 11 (8.7)  | 6 (7.4)   |        |
| 2                                    | 115 (7.3)   | 132 (11.9) | 4 (3.2)   | 11 (13.6) |        |
| 3                                    | 28 (1.8)    | 78 (7.1)   | 3 (2.4)   | 1 (1.2)   |        |
| **Tumor stage, n (%)**               |       |       |       |          |        |
| 0                                    | 263 (16.7)  | 195 (17.6) | 24 (19.0) | 9 (11.1)  | 0.097  |
| 1                                    | 628 (39.9)  | 372 (33.6) | 42 (33.3) | 30 (37.0) |        |
| 2                                    | 505 (32.1)  | 391 (35.4) | 43 (34.1) | 30 (37.0) |        |
| 3                                    | 179 (11.4)  | 148 (13.4) | 17 (13.5) | 12 (14.8) |        |
| **Estrogen receptor, n (%)**         |       |       |       |          |        |
| Negative                             | 284 (19.2) | 307 (30.3) | 16 (13.6) | 20 (25.3) | <0.001 |
| Positive                             | 1193 (80.8) | 706 (69.7) | 102 (86.4) | 59 (74.7) |        |
| **Progesterone receptor, n (%)**     |       |       |       |          |        |
| Negative                             | 458 (31.1) | 436 (43.0) | 29 (24.6) | 26 (32.9) | <0.001 |
| Positive                             | 1016 (68.9) | 578 (57.0) | 89 (75.4) | 53 (67.1) |        |
| **Her2 status, n (%)**               |       |       |       |          |        |
| Negative                             | 1051 (83.7) | 734 (83.1) | 76 (74.5) | 62 (87.3) | 0.084  |
| Positive                             | 204 (16.3) | 149 (16.9) | 26 (25.5) | 9 (12.7)  |        |
| **Molecular subtype, n (%)**         |       |       |       |          |        |
| ER/PR+, her2-                        | 884 (70.4) | 511 (57.9) | 68 (66.7) | 49 (69.0) | <0.001 |
| ER/PR+, her2+                        | 128 (10.2) | 90 (10.2)  | 18 (17.6) | 6 (8.5)   |        |
| ER/PR-, her2+                        | 76 (6.1)   | 58 (6.6)   | 8 (7.8)   | 3 (4.2)   |        |
| Triple negative                      | 167 (13.3) | 223 (25.3) | 8 (7.8)   | 13 (18.3) |        |
| **Histologic grade, n (%)**          |       |       |       |          |        |
| 1                                    | 230 (15.6) | 134 (12.8) | 21 (17.8) | 9 (11.5)  | <0.001 |
| 2                                    | 742 (50.3) | 456 (43.6) | 61 (51.7) | 41 (52.6) |        |
| 3                                    | 504 (34.1) | 456 (43.6) | 36 (30.5) | 28 (35.9) |        |
| **Type of surgery, n (%)**           |       |       |       |          |        |
| No surgery                           | 13 (0.8)   | 12 (1.1)   | 0 (0.0)   | 0 (0.0)   | <0.001 |
| Breast conserving surgery            | 913 (58.7) | 683 (65.1) | 62 (49.6) | 45 (57.7) |        |
| Mastectomy                           | 629 (40.5) | 354 (33.8) | 63 (50.4) | 33 (42.3) |        |
| **Chemotherapy, n (%)**              |       |       |       |          |        |
| No                                   | 881 (55.9) | 586 (53.0) | 71 (56.3) | 39 (48.1) | 0.28   |
| Yes                                  | 694 (44.1) | 520 (47.0) | 55 (43.7) | 42 (51.9) |        |
Hormonal therapy, n (%)

|                | No     |        | Yes     |        |
|----------------|--------|--------|---------|--------|
|                | 495 (31.4) | 462 (41.8) | 27 (21.4) | 28 (34.6) |
|                | <0.001  |        |         |        |

Radiotherapy, n (%)

|                | No     |        | Yes     |        |
|----------------|--------|--------|---------|--------|
|                | 657 (41.7) | 437 (39.5) | 63 (50.0) | 28 (34.6) |
|                | 0.074   |        |         |        |

BMI at baseline, n (%)

|                | Underweight |        | Normal weight |        | Overweight |        | Obese |        |
|----------------|-------------|--------|---------------|--------|------------|--------|-------|--------|
|                | 19 (1.4)    | 4 (0.5) | 548 (41.6)    | 143 (16.9) | 388 (29.5) | 261 (30.9) | 362 (27.5) | 438 (51.8) |
|                | 2 (2.0)     | 0 (0.0) | 58 (58.6)     | 13 (22.4) | 28 (28.3)  | 30 (51.7)  | 11 (11.1)  | 15 (25.9)  |

*Number (%) are presented if not otherwise specified and numbers are not added up to total due to missing data. In particular Her2 data were collected for few patients with stage 0 tumors.

Abbreviation: BMI, body mass index; SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor

**Table 2. Multivariable mixed effect linear model of body mass index among breast cancer patients**
### Table 3. Prognostic values of baseline body mass index at diagnosis: Cox models

|                              | BMI at baseline, kg/m² | Slope over time in BMI, kg/m²/year |
|------------------------------|-------------------------|-----------------------------------|
|                              | Mean (SE)* | P      | Mean (SE)* | P      |
| **Race/ethnicity**           |             |        |             |        |
| White                        | 27.85       | ref.   | -0.07 (0.02) | ref.   |
|                             | (0.17)      |        |             |        |
| Black                        | 31.88       | <0.001 | -0.47 (0.02) | <0.001 |
|                             | (0.20)      |        |             |        |
| Asian                        | 25.39       | <0.001 | -0.30 (0.05) | <0.001 |
|                             | (0.60)      |        |             |        |
| Hispanic                     | 29.54       | 0.023  | -0.08 (0.07) | 0.94   |
|                             | (0.73)      |        |             |        |
| **Age at diagnosis**         |             |        |             |        |
| < 50                         | 28.75       | ref.   | -0.16 (0.02) | ref.   |
|                             | (0.22)      |        |             |        |
| ≥ 50                         | 30.26       | <0.001 | -0.33 (0.01) | <0.001 |
|                             | (0.16)      |        |             |        |
| **Carlson comorbidity index at diagnosis** |             |        |             |        |
| 0                            | 29.30       | ref.   | -0.19 (0.01) | ref.   |
|                             | (0.15)      |        |             |        |
| 1+                           | 30.96       | <0.001 | -0.50 (0.02) | <0.001 |
|                             | (0.26)      |        |             |        |
| **Tumor stage**              |             |        |             |        |
| 0                            | 30.09       | 0.064  | -0.14 (0.03) | 0.82   |
|                             | (0.34)      |        |             |        |
| 1                            | 29.42       | ref.   | -0.15 (0.02) | ref.   |
|                             | (0.22)      |        |             |        |
| 2                            | 29.71       | 0.35   | -0.30 (0.02) | <0.001 |
|                             | (0.21)      |        |             |        |
| 3                            | 30.48       | 0.016  | -0.59 (0.03) | <0.001 |
|                             | (0.36)      |        |             |        |
| **Chemotherapy**             |             |        |             |        |
| No                           | 29.48       | ref.   | -0.32 (0.02) | ref.   |
|                             | (0.21)      |        |             |        |
| Yes                          | 30.00       | 0.10   | -0.25 (0.02) | 0.009  |
|                             | (0.20)      |        |             |        |
| **Smoking status at diagnosis** |             |        |             |        |
| Never                        | 29.56       | ref.   | -0.26 (0.01) | ref.   |
|                             | (0.16)      |        |             |        |
| Previous                     | 30.44       | 0.002  | -0.36 (0.02) | <0.001 |
|                             | (0.24)      |        |             |        |
| Current                      | 29.25       | 0.43   | -0.20 (0.03) | 0.11   |
|                             | (0.36)      |        |             |        |

*Multivariable fitted mean body mass index (BMI) and standard errors (SE) as well as the fitted mean slope of BMI over time are presented. All the variables in the table were included in the multivariable model.
### Table 4. Associations between changing slope in body mass index and clinical outcomes: Multivariable Cox models*

|                      | Univariate analysis |                      | Multivariable analysis* |
|----------------------|---------------------|-----------------------|-------------------------|
|                      | HR (95% CI)         | P                     | HR (95% CI)             | P  |
| **Overall survival** |                     |                       |                         |    |
| Categorical BMI      |                     |                       |                         |    |
| Overweight vs. normal| 1.65 (1.18-2.31)    | 0.004                 | 1.23 (0.85-1.79)        | 0.27|
| Obese vs. normal     | 1.85 (1.34-2.55)    | <0.001                | 1.15 (0.79-1.65)        | 0.47|
| Continuous BMI, per 5 kg/m² | 1.18 (1.10-1.28) | <0.001               | 1.09 (0.99-1.20)        | 0.073|
| **Breast cancer-specific survival** | |                       |                         |    |
| Categorical BMI      |                     |                       |                         |    |
| Overweight vs. normal| 1.86 (1.15-3.03)    | 0.012                 | 1.72 (1.01-2.93)        | 0.045|
| Obese vs. normal     | 1.74 (1.08-2.81)    | 0.023                 | 1.36 (0.79-2.33)        | 0.27|
| Continuous BMI, per 5 kg/m² | 1.11 (0.99-1.25) | 0.079               | 1.01 (0.87-1.16)        | 0.92|
| **Disease-free survival** | |                       |                         |    |
| Categorical BMI      |                     |                       |                         |    |
| Overweight vs. normal| 1.65 (1.25-2.18)    | <0.001                | 1.30 (0.96-1.76)        | 0.094|
| Obese vs. normal     | 1.67 (1.28-2.19)    | <0.001                | 1.09 (0.80-1.48)        | 0.59|
| Continuous BMI, per 5 kg/m² | 1.15 (1.08-1.23) | <0.001               | 1.04 (0.96-1.13)        | 0.37|

*Adjusted for age, race, Carlson comorbidity index, tumor stage, histologic grade, estrogen receptor, progesterone receptor, Her2, radiotherapy, hormonal therapy, and chemotherapy in delayed entry Cox models.

Abbreviations: BMI, body mass index; HR, hazard ratio; CI, confidence intervals.

---

*Multivariable analysis* refers to the adjusted analysis after controlling for various covariates.
|                                | Overall survival | Breast cancer-specific survival | Disease-free survival |
|--------------------------------|------------------|--------------------------------|-----------------------|
|                                | HR (95% CI)      | HR (95% CI)                    | HR (95% CI)           |
| **Changing slope in BMI**      |                  |                                |                       |
| Loss > 0.5 kg/m²/year           | 2.60 (1.88-3.59) | <0.001                         | 3.05 (1.91-4.86)      | <0.001                | 2.12 (1.52-2.96)      | <0.001 |
| Stable (≤0.5 kg/m²/year)        | 1.0 (ref.)       | 1.0 (ref.)                     | 1.0 (ref.)            |
| Gain > 0.5 kg/m²/year           | 1.60 (1.10-2.33) | 0.014                          | 1.73 (1.04-2.87)      | 0.035                 | 1.54 (1.06-2.24)      | 0.024 |
| **Race/ethnicity**             |                  |                                |                       |
| Black vs. White                 | 1.98 (1.49-2.64) | <0.001                         | 2.06 (1.40-3.04)      | <0.001                | 2.02 (1.51-2.69)      | <0.001 |
| Asian vs. White                 | 1.38 (0.59-3.18) | 0.46                           | 1.92 (0.75-4.90)      | 0.18                  | 1.21 (0.49-3.03)      | 0.68   |
| Hispanic vs. White              | 0.32 (0.08-1.30) | 0.11                           | 0.59 (0.14-2.45)      | 0.47                  | 0.31 (0.08-1.28)      | 0.11   |
| **Age per 10 years**           | 1.33 (1.19-1.49) | <0.001                         | 1.16 (1.01-1.34)      | 0.036                 | 1.35 (1.20-1.51)      | <0.001 |
| **Carlson comorbidity index**  |                  |                                |                       |
| 1 vs. 0                         | 1.28 (0.84-1.94) | 0.26                           | 1.41 (0.84-2.38)      | 0.20                  | 1.35 (0.88-2.09)      | 0.17   |
| 2 vs. 0                         | 2.62 (1.82-3.76) | <0.001                         | 1.28 (0.70-2.35)      | 0.43                  | 2.87 (1.99-4.13)      | <0.001 |
| 3 vs. 0                         | 3.36 (2.17-5.18) | <0.001                         | 1.05 (0.43-2.56)      | 0.91                  | 3.48 (2.24-5.41)      | <0.001 |
| **Tumor stage**                 |                  |                                |                       |
| 0 vs. 1                         | 0.67 (0.16-2.82) | 0.59                           | 0.0**                 | 0.68                  | 0.68 (0.16-2.87)      | 0.60   |
| 2 vs. 1                         | 1.34 (0.96-1.86) | 0.087                          | 2.42 (1.43-4.08)      | 0.001                 | 1.40 (1.00-1.97)      | 0.048  |
| 3 vs. 1                         | 2.71 (1.83-4.01) | <0.001                         | 5.92 (3.35-10.48)     | <0.001                | 2.46 (1.63-3.70)      | <0.001 |
| **Histologic grade**           |                  |                                |                       |
| 2 vs. 1                         | 1.48 (0.86-2.54) | 0.16                           | 4.41 (1.06-18.41)     | 0.042                 | 1.43 (0.85-2.39)      | 0.18   |
| 3 vs. 1                         | 1.76 (0.97-3.17) | 0.06                           | 7.32 (1.70-31.54)     | 0.008                 | 1.60 (0.91-2.84)      | 0.11   |
| **Molecular subtype**          |                  |                                |                       |
| ER/PR+, her2+ vs. ER/PR+/her2-  | 0.85 (0.52-1.40) | 0.53                           | 0.53 (0.26-1.10)      | 0.088                 | 0.80 (0.48-1.33)      | 0.38   |
| ER/PR-, her2+ vs. ER/PR+/her2-  | 0.86 (0.40-1.84) | 0.70                           | 0.93 (0.36-2.38)      | 0.88                  | 0.69 (0.31-1.55)      | 0.37   |
| Triple negative vs. ER/PR+/her2-| 1.19 (0.66-2.14) | 0.56                           | 1.28 (0.60-2.71)      | 0.53                  | 0.95 (0.52-1.74)      | 0.87   |
| Radiotherapy                    | 0.86 (0.65-1.14) | 0.30                           | 0.70 (0.48-1.02)      | 0.063                 | 1.02 (0.76-1.37)      | 0.91   |
|                      | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
|----------------------|-------------|---------|-------------|---------|-------------|---------|
| Hormonal therapy     | 0.93 (0.56-1.54) | 0.78 | 0.96 (0.48-1.92) | 0.91 | 0.96 (0.57-1.61) | 0.88 |
| Chemotherapy         | 1.10 (0.75-1.62) | 0.62 | 0.91 (0.52-1.57) | 0.73 | 1.25 (0.85-1.85) | 0.26 |

Abbreviation: HR, hazard ratio; CI, confidence intervals; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor

*All variables in the table are included in the three multivariable Cox models. **No DCIS patents died from breast cancer

**Table 5.** Associations between changing slope in body mass index and clinical outcomes: subgroup analysis.
|                      | Overall survival | Breast cancer-specific survival | Disease-free survival |
|----------------------|-----------------|---------------------------------|-----------------------|
|                      | Events /Persons | HR (95% CI)*                     | Events /Persons | HR (95% CI)* | Events /Persons | HR (95% CI)* |
| **In Whites**        |                 |                                 |                      |              |                  |              |
| Loss > 0.5 kg/m²/year| 40/285          | 2.22 (1.31-3.75)                | 20/285              | 1.75 (0.86-3.55) | 40/266          | 2.04 (1.21-3.44) |
| Stable (≤0.5 kg/m²/year) | 30/744     | 1.0 (ref.)                      | 18/744              | 1.0 (ref.)  | 31/706          | 1.0 (ref.)   |
| Gain > 0.5 kg/m²/year| 25/372          | 1.41 (0.79-2.51)                | 15/372              | 1.02 (0.47-2.19) | 22/348          | 1.33 (0.75-2.38) |
|                      |                 |                                 |                      |              |                  |              |
| **In Blacks**        |                 |                                 |                      |              |                  |              |
| Loss > 0.5 kg/m²/year| 93/280          | 2.80 (1.86-4.22)                | 46/280              | 4.27 (2.22-8.21) | 83/254          | 2.29 (1.50-3.49) |
| Stable (≤0.5 kg/m²/year) | 42/437     | 1.0 (ref.)                      | 14/437              | 1.0 (ref.)  | 46/409          | 1.0 (ref.)   |
| Gain > 0.5 kg/m²/year| 36/219          | 1.72 (1.05-2.84)                | 23/219              | 2.48 (1.21-5.08) | 37/205          | 1.78 (1.08-2.92) |
|                      |                 |                                 |                      |              |                  |              |
| Test for interaction |                 | 0.77                            |                      |              | 0.14             |              |
|                      |                 |                                 |                      |              | 0.76             |              |
| **In women with normal weight at diagnosis** | | | | | | |
| Loss > 0.5 kg/m²/year| 15/77           | 1.92 (0.91-4.05)                | 8/77                | 2.73 (0.90-8.31) | 15/74           | 1.91 (0.87-4.16) |
| Stable (≤0.5 kg/m²/year) | 22/445     | 1.0 (ref.)                      | 10/445              | 1.0 (ref.)  | 18/427          | 1.0 (ref.)   |
| Gain > 0.5 kg/m²/year| 10/182          | 0.99 (0.45-2.16)                | 6/182               | 1.33 (0.44-4.03) | 11/176          | 1.16 (0.53-2.55) |
|                      |                 |                                 |                      |              |                  |              |
| Test for interaction |                 | 0.32                            |                      |              | 0.98             |              |
|                      |                 |                                 |                      |              | 0.83             |              |
| **In women with overweight/obese at diagnosis** | | | | | | |
| Loss > 0.5 kg/m²/year| 85/414          | 3.07 (1.96-4.80)                | 46/414              | 3.08 (1.62-5.87) | 76/389          | 2.21 (1.41-3.45) |
| Stable (≤0.5 kg/m²/year) | 36/647     | 1.0 (ref.)                      | 16/647              | 1.0 (ref.)  | 44/613          | 1.0 (ref.)   |
| Gain > 0.5 kg/m²/year| 30/318          | 1.96 (1.14-3.37)                | 16/318              | 1.47 (0.69-3.12) | 27/304          | 1.56 (0.90-2.71) |
|                      |                 |                                 |                      |              |                  |              |
| Test for interaction |                 | 0.32                            |                      |              | 0.98             |              |
|                      |                 |                                 |                      |              | 0.83             |              |
| **In women ages <50** | | | | | | |
| Loss > 0.5 kg/m²/year| 24/135          | 3.94 (1.87-8.30)                | 17/135              | 3.40 (1.40-8.25) | 21/115          | 4.48 (2.05-9.79) |
| Stable (≤0.5 kg/m²/year) | 13/407     | 1.0 (ref.)                      | 10/407              | 1.0 (ref.)  | 11/372          | 1.0 (ref.)   |
| Gain > 0.5 kg/m²/year| 18/281          | 1.58 (0.74-3.39)                | 16/281              | 1.64 (0.69-3.90) | 16/259          | 1.65 (0.74-3.67) |
|                      |                 |                                 |                      |              |                  |              |
| **In women ages ≥50** | | | | | | |
| Loss > 0.5 kg/m²/year| 113/467         | 2.38 <0.001                     | 52/467              | 2.95 <0.001  | 104/439         | 1.83 0.001   |
Table 6. Prognostic values of changes in body mass index within the first two years since diagnosis: multivariable Cox models

|                  | Overall survival | Breast cancer-specific survival | Disease-free survival |
|------------------|------------------|---------------------------------|-----------------------|
|                  | Events /Persons  | HR (95% CI)*                    | P                     | Events /Persons  | HR (95% CI)*                    | P                     | Events /Persons  | HR (95% CI)*                    | P                     |
| Slope in the first 2 years after diagnosis |                  |                                 |                       |                  |                                 |                       |                  |                                 |                       |
| Loss > 0.5 kg/m²/year | 113/680          | 1.69 (1.20-2.40)                | 0.003                 | 60/680           | 2.00 (1.20-3.34)                | 0.008                 | 129/659          | 1.54 (1.13-2.11)                | 0.007                 |
| Stable (≤ 0.5 kg/m²/year) | 57/804          | 1.0 (ref.)                      |                       | 25/804           | 1.0 (ref.)                    |                       | 72/786           | 1.0 (ref.)                    |                       |
| Gain > 0.5 kg/m²/year | 59/775          | 1.10 (0.74-1.63)                | 0.63                  | 32/775           | 1.26 (0.72-2.22)               | 0.42                  | 86/757           | 1.16 (0.83-1.63)               | 0.39                  |
| Change from diagnosis to 18 months |                  |                                 |                       |                  |                                 |                       |                  |                                 |                       |
| Loss > 5% Stable (≤ 5%) | 65/356          | 1.60 (1.11-2.31)                | 0.012                 | 38/356           | 1.63 (0.99-2.69)               | 0.053                 | 65/346           | 1.33 (0.95-1.88)               | 0.099                 |
| Gain > 5% | 82/1127          | 1.0 (ref.)                      |                       | 40/1127          | 1.0 (ref.)                    |                       | 109/1106         | 1.0 (ref.)                    |                       |
|                  | 27/311           | 1.14 (0.72-1.81)                | 0.58                  | 13/311           | 0.95 (0.49-1.84)               | 0.89                  | 37/306           | 1.05 (0.70-1.57)               | 0.81                  |

*Adjusted for age, race, Carlson comorbidity index, tumor stage, histologic grade, molecular subtype, radiotherapy, hormonal therapy, and chemotherapy in delayed entry Cox models.

Abbreviations: BMI, body mass index; HR, hazard ratio; CI, confidence intervals.
Figure 1

Concordance plot of measured and self-reported height and weight. CCC, Lin's concordance correlation coefficient for agreement.
Figure 4

Relationship between changing slope of BMI over time (kg/m2/year) and three clinical outcomes: overall survival (A), breast cancer-specific survival (B), and disease-free survival (C). The curves were estimated from delayed entry Cox models of continuous BMI slopes fitted using restricted cubic spline, while the hazard ratios and 95% confidence intervals (CI) were estimated from Cox models that fit categorical BMI changing slopes with stable category as the reference category (BMI change less than 0.5kg/m2/year).